Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas

医学 耐受性 内科学 中性粒细胞减少症 不利影响 胃肠病学 肿瘤科 贾纳斯激酶 药理学 化疗 细胞因子
作者
Yuqin Song,Dok Hyun Yoon,Haiyan Yang,Junning Cao,Dongmei Ji,Youngil Koh,Hongmei Jing,Hyeon‐Seok Eom,Jae‐Yong Kwak,W. Robert Lee,J. Jack Lee,Ho‐Jin Shin,Jie Jin,Michael Wang,Zhi Yang,Woo Seob Kim,Jun Zhu
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34 (11): 1055-1063 被引量:11
标识
DOI:10.1016/j.annonc.2023.08.013
摘要

Relapsed or refractory peripheral T-cell lymphomas (r/r PTCLs) are a group of rare and aggressive diseases that lack effective therapies. Constitutive activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is reported to be associated with PTCLs. Golidocitinib is an oral, potent JAK1 selective inhibitor evaluated in a phase I/II multinational study in patients with r/r PTCLs.Patients with r/r PTCLs were eligible. The primary objectives were to assess safety and tolerability of golidocitinib and to define its recommended phase II dose (RP2D). The secondary objectives were to evaluate its antitumor activity and pharmacokinetics (PK).A total of 51 patients were enrolled and received golidocitinib treatment at 150 or 250 mg once daily (QD). The median prior lines of therapies were 2 (range: 1-8). Golidocitinib was tolerated at both doses tested, while a higher incidence of serious adverse events and dose modifications at 250 mg were observed. The most common grade ≥3 drug-related treatment-emergent adverse events were neutropenia (27.5%) and thrombocytopenia (11.8%). An objective response rate of 39.2% and a complete response rate of 21.6% were observed. With median follow-up time of 14.7 and 15.9 months, the median duration of response (DoR) and progression-free survival were 8.0 and 3.3 months, respectively. Based on these data, 150 mg QD was defined as the RP2D. Golidocitinib demonstrated a favorable PK profile as an oral agent. Biomarker analysis suggested a potential correlation between JAK/STAT pathway aberrations and clinical activity of golidocitinib.In this phase I study, golidocitinib demonstrated an acceptable safety profile and encouraging antitumor efficacy in heavily pretreated patients with r/r PTCLs. These results support the initiation of the multinational pivotal study in patients with r/r PTCLs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
YYY完成签到 ,获得积分10
刚刚
刚刚
huang发布了新的文献求助10
刚刚
刚刚
思源的应助被YOUYOURS采纳,获得10
2秒前
香蕉觅云的应助被杨媛采纳,获得10
2秒前
周一发布了新的文献求助10
2秒前
桃汁发布了新的文献求助10
3秒前
科研通AI65的应助被LFY采纳,获得10
3秒前
多喝水呀完成签到 ,获得积分10
5秒前
悦耳的城发布了新的文献求助10
5秒前
RENZHIJIA完成签到,获得积分10
6秒前
酷波er的应助被nature大牛采纳,获得10
6秒前
落日下的蒲公英完成签到 ,获得积分10
6秒前
7秒前
7秒前
0896完成签到,获得积分10
8秒前
Lzy完成签到 ,获得积分10
8秒前
cdercder的应助被XX采纳,获得10
8秒前
9秒前
10秒前
外向白竹完成签到,获得积分10
10秒前
科研通AI2S的应助被donwe采纳,获得10
10秒前
天天快乐的应助被虎王采纳,获得10
11秒前
11秒前
拼搏的依风完成签到 ,获得积分10
12秒前
现在发布了新的文献求助10
12秒前
huang完成签到,获得积分10
12秒前
晴天白敬亭完成签到 ,获得积分10
13秒前
Tracy完成签到,获得积分10
13秒前
六六柳柳发布了新的文献求助10
13秒前
汉堡包的应助被一木采纳,获得10
14秒前
14秒前
多喝水呀发布了新的文献求助10
14秒前
杭黎昕完成签到,获得积分10
15秒前
15秒前
直率黑夜完成签到,获得积分20
15秒前
wzwzwz完成签到 ,获得积分20
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193925
求助须知:如何正确求助?哪些是违规求助? 9579945
关于积分的说明 21868504
捐赠科研通 7793568
什么是DOI,文献DOI怎么找? 3437462
关于科研通互助平台的介绍 2560923
邀请新用户注册赠送积分活动 2484250